4 Likely Biotech Takeover Targets To Buy
July 23, 2016 at 17:53 PM EDT
After biotech stock Relypsa was bought out last week for a 60% premium, the odds of M&A heating up in this sector increased dramatically. Bret Jensen shares four more likely takeover targets that should be on your watchlist.
